Sanaria~R PfSPZ malaria vaccine wins 2014 Vaccine Industry Excellence award for 'Best Prophylactic Vaccine'

摘要

Sanaria received the 2014 Vaccine Industry Excellence Award for the "Best Prophylactic Vaccine" at a ceremony held in Washington DC during the 14th World Vaccine Congress. Vaccines from Sanofi Pasteur, GSK, and Novartis were among the 6 finalists competing with Sanaria. The awardee, Sanaria~R PfSPZ Vaccine, demonstrated complete protection against malaria in all volunteers (6/6) who received high dose immunizations in a trial at the Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID), NIH. The clinical trial results were published online in Science magazine in August 2013. Additional safety, efficacy and regimen refinement studies are underway led by teams from the VRC, NIAID, NIH and the University of Maryland, School of Medicine in the US, and from the University of Bamako and the Laboratory of Malaria Immunology and Vaccinology (LMIV), NIAID, in Mali. Trials of PfSPZ Vaccine are also planned to begin in the next few months at the Ifakara Health Institute,Tanzania, the Naval Medical Research Center and Walter Reed Army Institute of Research, USA, Ministry of Health, Equatorial Guinea, and the University of Tubingen, Germany. Sanaria has pioneered the manufacture, storage, shipping, and administration ofPlasmodium falciparum sporozoite stage malaria parasites as vaccines. With collaborating partners in the US, Europe, and Africa, Sanaria is optimizing vaccine dosage regimens and performance characteristics and establishing operational systems for mass administration of PfSPZ Vaccine to be used in malaria elimination campaigns.